LOC100996412: A Drug Target / Disease Biomarker (G100996412)
LOC100996412: A Drug Target / Disease Biomarker
LOC100996412 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the T-cell receptor (TCR) family, which is a critical signaling pathway in the immune system.
The TCR is composed of two heavy chains and two light chains that are held together by disulfide bonds. The heavy chains contain the variable regions of the TCR, which are responsible for recognizing specific antigens. The light chains contain the constant regions of the TCR, which provide structural stability to the complex.
LOC100996412 is a 21-kDa protein that is expressed in the TCR尾 chain. The TCR尾 chain is composed of 15 constant and 6 variable regions. The variable regions of TCR尾 contain the majority of the antigen recognition sites, including the J-shaped selectivity motif (SHM) and the variable regions that interact with the antigens.
The SHM is a crucial motif that is present in many TCRs, including TCR尾. It is a short, looping region that is responsible for recognizing specific alpha-helices in antigens. The SHM is thought to play a critical role in the recognition of self-antigens, such as viruses and cancer cells, while it is not involved in the recognition of alligens.
LOC100996412 is a perfect candidate for drug targeting because it is involved in the recognition of foreign antigens and it's a protein that is expressed in various tissues of the body. This means that if a drug can be developed to interact with LOC100996412, it can potentially be used to treat a wide range of diseases.
One of the main advantages of targeting LOC100996412 is that it is a protein that is expressed in many different tissues of the body, which means that a drug that targets this protein could potentially be used to treat a wide range of diseases. For example, LOC100996412 is expressed in the brain, heart, and kidneys, which are all critical organs that could be affected by a wide range of diseases. Additionally, because LOC100996412 is a protein that is involved in the immune response, targeting it with a drug could potentially be used to treat a wide range of autoimmune diseases.
Another advantage of targeting LOC100996412 is that it is a protein that is involved in many different signaling pathways. As mentioned earlier, LOC100996412 is a member of the TCR family, which is involved in the immune response. Additionally, LOC100996412 is involved in the regulation of cell growth and differentiation, which is thought to be a critical role in the development and progression of many diseases.
Finally, targeting LOC100996412 is a great opportunity for researchers to gain new insights into the biology of this protein and its role in the immune response. By studying LOC100996412, researchers will be able to gain a better understanding of how this protein functions and how it contributes to the immune response. This knowledge could potentially lead to the development of new treatments for a wide range of diseases.
In conclusion, LOC100996412 is a protein that is expressed in various tissues of the body and it is a member of the T-cell receptor family. It is a great candidate for drug targeting because it is involved in the recognition of foreign antigens, it is expressed in many different tissues of the body, and it is involved in many different signaling pathways. Additionally, it is a great opportunity for researchers to gain new insights into the biology of this protein and its role in the immune response.
Protein Name: Uncharacterized LOC100996412
The "LOC100996412 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC100996412 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC100996583 | LOC100996637 | LOC100996643 | LOC100996664 | LOC100996770 | LOC101060017 | LOC101060106 | LOC101060179 | LOC101060400 | LOC101060445 | LOC101060524 | LOC101060632 | LOC101448202 | LOC101593348 | LOC101926887 | LOC101926948 | LOC101926953 | LOC101926959 | LOC101926969 | LOC101927002 | LOC101927020 | LOC101927025 | LOC101927026 | LOC101927040 | LOC101927053 | LOC101927060 | LOC101927066 | LOC101927082 | LOC101927108 | LOC101927143 | LOC101927164 | LOC101927166 | LOC101927169 | LOC101927179 | LOC101927188 | LOC101927199 | LOC101927216 | LOC101927243 | LOC101927245 | LOC101927253 | LOC101927263 | LOC101927269 | LOC101927314 | LOC101927369 | LOC101927394 | LOC101927421 | LOC101927476 | LOC101927483 | LOC101927495 | LOC101927518 | LOC101927531 | LOC101927548 | LOC101927550 | LOC101927571 | LOC101927588 | LOC101927598 | LOC101927605 | LOC101927609 | LOC101927627 | LOC101927636 | LOC101927668 | LOC101927712 | LOC101927727 | LOC101927741 | LOC101927745 | LOC101927770 | LOC101927787 | LOC101927825 | LOC101927827 | LOC101927834 | LOC101927840 | LOC101927853 | LOC101927855 | LOC101927857 | LOC101927863 | LOC101927896 | LOC101927897 | LOC101927910 | LOC101927932 | LOC101927942 | LOC101927947 | LOC101927960 | LOC101927967 | LOC101927971 | LOC101927995 | LOC101927998 | LOC101928004 | LOC101928007 | LOC101928008 | LOC101928012 | LOC101928014 | LOC101928047 | LOC101928053 | LOC101928080 | LOC101928093 | LOC101928120 | LOC101928135 | LOC101928143 | LOC101928152 | LOC101928163
